Video Library
Hear expert commentary on ovarian function suppression (OFS) side effect management, including strategies used to address psychosocial challenges affecting premenopausal breast cancer patients undergoing OFS.
Listen as a nurse navigator discusses ovarian function suppression (OFS) and the subsequent impact of OFS on premenopausal women with breast cancer.
Polly Niravath, MD, discusses fertility preservation in premenopausal women with breast cancer who are undergoing ovarian function suppression (OFS) treatment.
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.
Dr Tolaney of Dana-Farber Cancer Institute reviews data on HER2CLIMB-02 and contributes future considerations of tucatinib in the metastatic HER2-positive breast cancer setting.
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center provides her insights on the practical aspects of the reported results of the INAVO120 phase 3 study.
Dr Tolaney of Dana-Farber Cancer Institute discusses her perspectives on the clinically meaningful overall survival outcomes of abemaciclib added to a nonsteroidal aromatase inhibitor as initial therapy in patients with HR+/HER2- advanced breast cancer.
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
This second installment discusses data presented at ESMO 2023 on prognostic markers for patients with early breast cancer, highlighting data from the monarchE study, the NATALEE study, and the BCIRG 001 and 005 trials.
This third installment observes data presented at ESMO 2023 on neoadjuvant immunotherapy in breast cancer, with a discussion of the KEYNOTE-522 study, NeoTRIP study, KEYNOTE-756 study, and the EMBER-2 study.
In this inaugural video, the panel provides peer-to-peer perspectives on educating the care team and patients on the new classification of HER2-low mBC.
In this second installment, our expert panel suggests approaches to empowering patients to become involved in shared decision-making.